Nonimmunosuppressive therapy of membranous nephropathy

Arrigo Schieppati, Piero Ruggenenti, Annalisa Perna, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalSeminars in Nephrology
Issue number4
Publication statusPublished - Jul 2003

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Nonimmunosuppressive therapy of membranous nephropathy'. Together they form a unique fingerprint.

Cite this